Diadia
Our TechnologyResourcesAboutLoginBook a call

© 2026 Diadia. All rights reserved.

About UsOur TechnologyResearchResources
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions
About UsOur TechnologyResearchResources
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions

© 2026 Diadia. All rights reserved.

←Transparency Reports

cardiovascular · Mechanism Report

Does elevated TMAO promote inflammatory signaling and cardiovascular risk?

Elevated TMAO is linked to inflammatory signaling and higher cardiovascular risk.

PlausibleAugust 21, 20269 Sources

Reasoning Paths

Each route from condition to outcome carries a support score — the product of its edge weights. Select one to isolate it on the figure.

This is what AI claimed

Elevated TMAO can promote inflammatory signaling and is associated with cardiovascular risk

laying out figure…
2 of 3 paths supported
UnsupportedPlausibleSupported

How to read the figure

Evidence state

  • ●EstablishedStrong, replicated evidence.
  • ◐ModerateEvidence-informed; limited or moderate.
  • ◇PlausibleMechanistically coherent, not established.
  • ✕UnsupportedTested and not supported — link breaks.
  • ?MissingNo evidence either way — untested.

Node shapes

  • BiomarkerA measurable state — a lab value, hormone, or genetic factor.
  • ProcessA biological process, pathway, or mechanism step.
  • ConditionA condition, exposure, intervention, or symptom.
  • OutcomeThe endpoint the claim leads to.

Executive summary

The claim says elevated trimethylamine N-oxide may drive inflammatory pathways while also tracking with cardiovascular events. The mechanism graph frames this through oxidative stress, inflammasome activation, and downstream inflammatory signaling in vascular cells. Overall, the conclusion presents TMAO as a risk-associated biomarker rather than a proven standalone causal target.

Verified conclusion

Elevated trimethylamine N-oxide (TMAO) is linked to vascular inflammatory pathways in experimental models and to higher cardiovascular event rates in prospective cohorts. For a 71-year-old man, renal function and established cardiovascular risk factors are particularly important when interpreting an elevated result.

Clinical and cardiovascular evidence

  • Across 11 prospective cohorts (10,245 participants), higher TMAO was associated with cardiovascular events (adjusted HR 1.23, 95% CI 1.07–1.42). A 19-study meta-analysis reported a major adverse cardiovascular event RR of 1.62 (95% CI 1.45–1.80); a 27-cohort synthesis found a smaller association (HR 1.032, 95% CI 1.014–1.051).
  • Renal function materially changes interpretation. In older adults, the highest versus lowest serial-TMAO quintile predicted incident ASCVD before eGFR adjustment (HR 1.21, 1.02–1.42), but not afterward (HR 1.07, 0.90–1.27). Associations were present with eGFR <60 mL/min/1.73 m² (HR 1.56, 1.13–2.14) but not preserved kidney function (HR 1.03, 0.85–1.25).

Mechanistic evidence

  • In human endothelial cells, TMAO activates p38/ERK/NF-κB signaling, NF-κB nuclear localization, and inflammatory mediators including COX-2, IL-6, E-selectin, and ICAM-1; NF-κB blockade prevented inflammatory gene induction and leukocyte adhesion.
  • TMAO also induces endothelial oxidative stress, activating the ROS–TXNIP–NLRP3 inflammasome pathway. NLRP3/caspase-1 signaling increases IL-1β and IL-18, while antioxidant, inflammasome, or caspase-1 interventions attenuate these effects. Human macrophages similarly show increased IL-1β, IL-6, TNF-α, TLR2, and NOX2 expression.

Bottom line

  • TMAO can promote inflammatory signaling experimentally and is consistently associated with cardiovascular risk, but it remains a prognostic marker rather than a proven causal, stand-alone treatment target. Its interpretation should be integrated with kidney function, diet, and conventional cardiovascular risk assessment.

References

  1. Trimethylamine N‐Oxide Promotes Vascular Inflammation Through ... — pmc.ncbi.nlm.nih.gov ↗
  2. Trimethylamine N-oxide induces inflammation and ... - PubMed — pubmed.ncbi.nlm.nih.gov ↗
  3. [PDF] Investigation of the effect of trimethylamine-N-oxide on the ... — applications.emro.who.int ↗
  4. Trimethylamine‐N‐Oxide Induces Vascular Inflammation by Activating the NLRP3 Inflammasome Through the SIRT3‐SOD2‐mtROS Signaling Pathway | Journal of the American Heart Association — ahajournals.org ↗
  5. Trimethylamine-N-Oxide Instigates NLRP3 Inflammasome Activation ... — pmc.ncbi.nlm.nih.gov ↗
  6. Circulating trimethylamine N‐oxide and the risk of cardiovascular ... — pmc.ncbi.nlm.nih.gov ↗
  7. Association of Trimethylamine-N-Oxide Levels with Risk of ... — karger.com ↗
  8. Gut Microbiota Metabolites and Risk of Major Adverse Cardiovascular Disease Events and Death: A Systematic Review and Meta‐Analysis of Prospective Studies | Journal of the American Heart Association — ahajournals.org ↗
  9. Longitudinal Plasma Measures of Trimethylamine N‐Oxide and Risk of Atherosclerotic Cardiovascular Disease Events in Community‐Based Older Adults | Journal of the American Heart Association — ahajournals.org ↗

See a full patient report verified like this

Book a walkthrough

Related Claims

Plausible10 sourcesAre F2-isoprostanes biomarkers of lipid peroxidation and does oxidized LDL contribute to atherosclerosis?→Plausible10 sourcesDo hs-CRP, Lp-PLA2, and myeloperoxidase reflect different cardiovascular risk signals?→